1 active not recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Donna Hammond, PhD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy Nicotinamide riboside, Placebo capsules - Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Active not recruiting | Donna Hammond, PhD | 48 | 2020-02-19 | 2026-08-20 |
| NR in Chemo-induced Peripheral Neuropathy Nicotinamide Riboside - Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic | Phase 2 | Terminated | Donna Hammond, PhD | 5 | 2019-11-08 | 2023-04-12 |
Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Peripheral Nervous System Diseases (1)
nicotinamide-beta-riboside (2)
United States (2)
Alexandra Thomas, MD (1) · Donna Hammond, Ph.D. (1) · Donna L Hammond, PhD (1) · Michael Shy, M.D. (1) · Mohammed Milhem, M.D. (1)
R21CA208968 (1)